Iron and neoplasia

Journal of Hepatology, Supplement

Volumn 28, Issue 1, 1998, Pages 21-25

  Deugnier, Yves ^a  

^a Laboratoire d'Anatomie Pathologique B   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; DEFEROXAMINE; FERRITIN; FERRITIN ANTIBODY; IMMUNOTOXIN; IRON; NITRILOTRIACETATE IRON; RECEPTOR ANTIBODY; RETINOL; SUPEROXIDE DISMUTASE; TOCOPHEROL; TRANSFERRIN; TRANSFERRIN RECEPTOR;

BLOOD DONOR; CANCER PATIENT; CARCINOGENESIS; CASE CONTROL STUDY; HEMOCHROMATOSIS; HETEROZYGOTE; HUMAN; IMMUNE SYSTEM; INDUSTRIAL WORKER; IRON BINDING CAPACITY; IRON CHELATION; IRON INTAKE; IRON METABOLISM; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LIVER DISEASE; LUNG CARCINOMA; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SARCOMA;

HUMANS; IRON; IRON, DIETARY; LIVER NEOPLASMS; OXIDATIVE STRESS;

EID: 0031982371     PISSN: 01695185     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Deugnier Y, Loréal O. Iron as a carcinogen. In: Barton JC, Edwards CQ, editors. Hemochromatosis. Cambridge: Cambridge University Press; 1998: in press.
2. Gonzales J, Benirchke K, Saltman P, Roberts J, Robinson P. Hemosiderosis in lemurs. Zoo Biol 1984; 3: 255-65.
3. Randell MG, Patnaik AK, Gould WJ. Hepatopathy associated with excessive iron storage in Mynah birds. J Am Vet MedAssocl981; 179: 1214-7.
4. Kalo J, Kobune Y, Kohgo Y, Sugawara N, Katsuki S, Shintani N, et al. Hepatic iron deprivation prevents spontaneous development of fulminant hepatitis and liver cancer in LongEvans Cinnamon rats. J Clin Invest 1996; 98: 923-9.
5. Rothenberg BE, Voland JR. Beta2 knockout mice develop parenchymal iron overload: a putative role for class I genes. of the major histocompatibility complex in iron metabolism. Proc Natl Acad Sei USA 1996; 93: 1529-34.
6. Stâl P, Hultcrantz R, Moller L, Eriksson L. The effects of dietary iron on initiation and promotion in chemical hepatocarcinogenesis. Hepatology 1995; 21: 521-8.
7. Pietrangelo A, Rocchi E, Schiaffonati L, Ventura E, Cairo G. Liver gene expression during chronic dietary iron overload in rats. Hepatology 1990; 111: 798-804.
8. Smith PG, Yeoh GCT. Chronic iron overload in rats induces oval cells in the liver. Am J Pathol 1996; 149: 389-98.
9. Pigeon C, Turlin B, lancu T, Lelan J, Leroyer P, Deugnier Y, et al. Carbonyl iron supplementation induces hepatocyte nuclear changes in BALB/cJ male mice. Hepatology 1997; 26: 342A.
10. Weinberg ED. Roles of iron in neoplasia. Promotion, prevention, and therapy. Biol Trace El Res 1992; 34: 1230.
11. Okada S. Iron-induced tissue damage and cancer: the role of reactive oxygen species-free radicals. Pathol Int 1996: 46: 331-2.
12. Halliday J\V, Searle J. Hepatic iron deposition in human disease and animal models. BioMetals 1996; 9: 205-9.
13. Toyokuni S. Iron-induced carcinogenesis: the role of redox regulation. Free Radie Biol Med 1996; 20: 553-66.
14. Selby JV, Friedman GD. Epidemiologie evidence of an association between body iron stores and risk of cancer. Int J Cancer 1988; 41: 677-82.
15. Stevens R, Jones Y, Micozzi M, Taylor P. Body iron stores and the risk of cancer. N EngI J Med 1988; 319: 1047-52.
16. Knekt P, Reunamen A, Takkunen H, Aromaa A, Heliovaara M, Hakulinen T. Body iron stores and risk of cancer. Int J Cancer 1994; 56: 379-82.
17. Stevens RG, Graubard BI, Micozzi MS, Neriishi K, Blumberg BS. Moderate elevation of body iron level and increased risk of cancer occurrence and death. Int J Cancer 1994; 56: 364-9.
18. Van Asparen IE, Feskens EJM, Bowles CH, Kromhout D. Body iron stores and mortality due to cancer and ischaemic heart disease: a 17-year follow-up study of elderly men and women. Int J Epidemiol 1995; 24: 665-70.
19. Herrinton LJ, Friedman GD, Baer D, Selby JV. Transferrin saturation and risk of cancer. Am J Epidemiol 1995; 142: 692-8.
20. Brissot P, Kerry D, Verger JP, Messner M, Regnouard F, Ferrand B, et al. Assessment of liver iron content in 271 patients: réévaluation of direct and indirect methods. Gastroenterology 1981; 80: 557-65.
21. Stevens RG, Kuvibidila S, Kapps M, Friedlaender J, Blumberg BS. Iron-binding proteins, hepatitis B virus, and mortality in the Salomon Islands. Am J Epidemiol 1983; 118: 550-61.
22. Stevens R, Beasley R, Blumberg B. Iron-binding proteins and risk of cancer in Taiwan. J Natl Cancer Inst 1986; 76: 60510.
23. Gordeuk VR, McLaren CE, MacPhail AP, Deichsel G, Bothwell TH. Associations of iron overload in Africa with hepatocellular carcinoma and tuberculosis: Strachan's 1929 thesis revisited. Blood 1996; 87: 3470-6.
24. Nelson RL, Davis FG, Sutler E, Sobin LH, Kikendall JW, Bowen P. Body iron stores and risk of colonie neoplasia. J Natl Cancer Inst 1994; 86: 455-60.
25. Bird CL, Witte JS, Swendsied ME, Shikany JM, Hunt IF, Frankl HD, et al. Plasma ferritin, iron intake, and the risk of colorectal polyps. Am J Epidemiol 1996; 144: 34-41.
26. Tseng M, Murray SC, Kupper LL, Sandier RS. Micronutrients and the risk of colorectal adenomas. Am J Epidemiol 1996; 144: 1005-14.
27. Merk K, Mattsson B, Holm G, Gullbring B, Björkholm M. The incidence of cancer among blood donors. Int J Epidemiol 1990; 19: 505-9.
28. Icso J, Szollosova M, Sorahan T. Lung cancer among iron ore miners in east Slovakia. Occup Environ Med 1994; 51: 642-3.
29. Mandel JS, McLaughlin JK, Schlehofer B, Mellemgaard A, Helmert U, Linblad P, et al. International renal-cell cancer study. IV. Occupation. Int J Cancer 1995: 61: 601-5.
30. Hann HWL, Y KC, London WT, Blumberg BS. Increased serum ferritin in chronic liver disease: a risk factor for primary hepatocellular carcinoma. Int J Cancer 1989; 43: 376-9.
31. Turlin B, Juguet F, Le Quilleuc D, Loréal O, Campion JP, Launois B, et al. Increased liver iron stores in patients with hepatocellular carcinoma developed on a non-cirrhotic liver. Hepatology 1995; 22: 446-50.
32. Niederau C, Fischer R, Pürschel A, Stremmel W, Häussinger D. Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996; 110: 1107-19.
33. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch H, Strohmeyer G. Survival and causes of death in cirrhotic and non-cirrhotic patients with primary hemochromatosis. N Engl J Med 1985: 313: 1256-62.
34. Bradbear RA, Bain C, Siskind V, Schofield FD, Webb S, Axelsen EM, et al. Cohort study of internal malignancy in genetic hemochromatosis and other chronic non-alcoholic liver disease. J Natl Cancer Inst 1985; 75: 81-4.
35. Fargion S, Mandelli C, Piperno A, Cesana B, Fracanzani A, Fraquelli M, et al. Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis. Hepatology 1992; 15: 655-9.
36. Fargion S, Fracanzani A, Piperno A, Braga M, D'Alba R, Ronehi G, et al. Prognostic factors for hepatocellular carcinoma in genetic hemochromatosis. Hepatology 1994; 20: 1426-31.
37. Deugnier Y, Guyader D, Crantoek L, Lopez JM, Turlin B, Yaouanq J, et al. Primary liver cancer in genetic hemochromatosis: a clinical, pathological and pathogenetic study of 54 cases. Gastroenterology 1993; 104: 228-34.
38. Adams PC, Speechley M, Kertesz AK. Long-term survival analysis in hereditary hemochromatosis. Gastroenterology 1991; 101: 368-72.
39. Nelson RL, Davis FG, Persky V, Becker E. Risk of neoplastic and other diseases among people with heterozygosity for hereditary hemochromatosis. Cancer 1995; 76: 875-9.
40. Deugnier Y, Turlin B, Powell L, Summers KM, Moirand R, Fletcher L, et al. Differentiation between hétérozygotes and homozygotes in genetic hemochromatosis by means of a histological hepatic iron index: a study of 192 cases. Hepatology 1993; 17: 30-4.
41. Bulaj ZJ, Griffen LM, Jorde LB, Edwards CQ, Kushner JP. Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. N Engl J Med 1996; 335: 1799805.
42. Bacon BR, Britton RS. The pathology of hepatic iron overload: a free radical-mediated process? Hepatology 1990; 11: 127-37.
43. Meneghini R. Iron homeostasis, oxidative stress, and DMA damage. Free Radie Biol Med 1997; 23: 783-92. ;''
44. Toyokuni S, Mori T, Dizdaroglu M. DNA base modifications in renal chromatin of Wistar rats treated with a renal carcinogen, ferric nitrilotriacetate. Int J Cancer 1994; 57: 123-8.
45. Loeb LA, James EA, Waltersdorph AM, Klebanoff Si. Mutagenesis by the autooxidation of iron with isolated DNA. Proc Natl Acad Sei USA 1988; 85: 3918-22.
46. Breimer LH. Repair of DNA damage induced by reactive oxygen species. Free Radie Res Commun 1991; 14: 159-71.
47. Aruoma O, Bomford A. Poison RJ. Non-transferrin bound iron in plasma from haemochromatosis patients: effect of phlebotomy therapy. Blood 1988; 72: 1416-9.
48. Young IS, Trouton TG, Torney JJ, McMaster D, Callender ME, Trimble ER. Antioxidant status and lipid peroxidation in hereditary haemochromatosis. Free Radie Biol Med 1994; 16: 393-7.
49. Houglum K, Ramm GA, Crawford DHG, Witztum JL, Powell LW, Chojkier M. Excess iron induces hepatic oxidative stress and transforming growth factor \in genetic hemochromatosis. Hepatology 1997; 26: 605-10.
50. Anghileri LJ, Thouvenot P. Non-transferrin-bound iron and tumor cells. Anticancer Res 1997; 17: 2529-34.
51. Hann HW, Stahlhut MW, Hann CL. Effect of iron and desferoxamine on cell growth and in vitro ferritin synthesis in human hepatoma cell lines. Hepatology 1990; 11: 566-9.
52. Brodie C, Siriwardana G, Lucas J, Schleicher R, Terada N, Szepesi A, et al. Neuroblastoma sensitivity to growth inhibition by deferoxamine: evidence for a block in Gl phase of the cell cycle. Cancer Res 1993; 53: 3968-75.
53. Hsieh-Ma ST, Shi T, Reeder J, Ring DB. In vitro tumor growth inhibition by bispecific antibodies to human transferrin receptor and tumor-associated antigens is augmented by the iron chelator deferoxamine. Clin Immunol Immunopathol 1996; 80: 185-93.
54. Lustbader E, Hann H, Blumberg B. Serum ferritin as a predictor of host response to hepatitis B virus infection. Science 1983; 220: 423-5.
55. Zhou XD, DeTolla L, Custer P, London WT. Iron, ferritin, hepatitis B surface and core antigens in the livers of Chinese patients with hepatocellular carcinoma. Cancer 1987; 59: 1430-7.
56. Williams GM, Yamamoto RS. Absence of stainable iron from pre-neoplastic and neoplastic lesions in rat liver with 8hydroxyquinoline induced siderosis. J Natl Cancer Inst 1972; 49: 685-92.
57. Deugnier YM, Charalambous P, Le Quilleuc D, Turlin B, Searle J, Brissot P, et al. Preneoplastic significance of hepatic iron-free foci in genetic hemochromatosis: a study of 185 patients. Hepatology 1993; 18: 1363-9.
58. Djeha A, Brock JH. Effect of transferrin, lactoferrin and chelated iron on human T-lymphocytes. Br J Haematol 1992; 80: 235-41.
59. Brock JH. Iron in infection, immunity, inflammation and neoplasia. In: Brock J, Halliday J, Pippard M, Powell L, editors. Iron Metabolism in Health and Disease. London: WB Saunders Company Ltd, 1994; 354-89.
60. Green R, Esparza I, Schreiber R. Iron inhibits the nonspecific tumoricidal activity of macrophages. A possible contributory mechanism for neoplasia in hemochromatosis. Ann NY Acad Sei 1988; 526: 301-9.
61. Hann HW, Stahlhut MW, Rubin R, Maddrey WC. Antitumor effect of deferoxamine on human hepatocellular carcinoma growing in athymic nude mice. Cancer 1992; 70: 20516.
62. Trowbridge IS. Potential uses of anti-transferrin receptor monoclonal antibodies. In: de Sousa M, Brock J, editors. Iron in Immunity, Cancer and Inflammation. Chichester: John Wiley; 1989. p. 314-60.
63. White S, Taetle R, Seligman P, Rutherford M, Trowbridge IS. Combination of anti-transferrin receptor monoclonal antibodies inhibits human tumor cell growth in vitro and /';/ vivo: evidence for synergestic antiproliferative effects. Cancer Res 1990; 50: 6295-301.
64. Kemp JD, Thorson JA, Stewaert B, Naumann PW. Inhibition of hematopoietic tumor growth by combined treatment with deferoxamine and an IgG monoclonal antibody against the transferrin receptor: evidence for a threshold model of iron deprivation toxicity. Cancer Res 1992; 52: 4144-18.
65. Donfrancesco A, Deb G, Dominici C, Pileggi D, Castello MA, Helson L. Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res 1990; 50: 4929-30.
66. Weitman SD, Buchanan GR, Kaman BA. Pulmonary toxicity of deferoxamine in children with advanced cancer. J Natl Cancer Inst 1991; 83: 1834-5.
67. Cazzola M, Bergamaschi G, Dezza L, Arosio P. Manipulations of cellular iron metabolism for modulating normal and malignant cell proliferation: achievements and prospects. Blood 1990; 75: 1903-19.
68. Order S, Pajak T, Leibel S, Asbell S, Leichner P, Ettinger D, et al. A randomized prospective trial comparing full dose chemotherapy to 1311 antiferritin: a RTOG study. Int J Radiât Oncol Biol Phys 1991; 20: 953-63.
69. Lenhard REJ, Order SE, Spunberg JJ, Asbell SO, Leibel SA. Isotopic immunoglobulin: a new systemic therapy for advanced Hodgkin's disease. J Clin Oncol 1985; 3: 1296-300.